fbpx

Check out the latest episodes of our Life Science and Food Industry Podcasts. Available everywhere!

X

First FDA-Approved Treatment for Chronic Yeast Infection + Eli Lilly Obesity Drug Shows Promise in Trials – Xtalks Life Science Podcast Ep. 59

First FDA-Approved Treatment for Chronic Yeast Infection + Eli Lilly Obesity Drug Shows Promise in Trials – Xtalks Life Science Podcast Ep. 59

In this episode, Ayesha discussed the FDA approval of Mycovia Pharmaceuticals’ Vivjoa (oteseconazole) as the first approved treatment for recurrent vulvovaginal candidiasis (RVVC) or chronic yeast infection. The drug is indicated for women who permanently lack reproductive potential or are postmenopausal. The editorial team discussed the significant unmet need for this condition and how although many women’s health issues are now given greater spotlight, there still need to be more conversations around them.

The episode marked World Maternal Mental Health Day and was sponsored by Elligo Health Research.

The editorial team also talked about the latest results of Eli Lilly’s investigational obesity drug tirzepatide, which demonstrated it could reduce body weight by an average of 20 percent in individuals without diabetes. Tirzepatide is a GLP-1 receptor agonist, a class of drugs designed to treat diabetes but at higher doses, can help with weight loss. Hear more about the drug and the obesity drug market, which is projected to grow to $5.42 billion in 2025.

Listen on Apple Podcasts

Read the full articles here:

Oteseconazole (Vivjoa) Becomes First FDA-Approved Drug for Recurrent Yeast Infection

Tirzepatide Obesity Drug Shown to Reduce Body Weight by 20 Percent in Eli Lilly Trial

The weekly podcast is available for streaming every Wednesday on SpotifyApple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.